AbbVie Inc. (ABBV)

87.91
0.95 1.10
NYSE : Health Technology
Prev Close 86.96
Open 86.67
Day Low/High 84.60 / 87.88
52 Wk Low/High 77.50 / 125.86
Volume 5.18M
Avg Volume 6.24M
Exchange NYSE
Shares Outstanding 1.50B
Market Cap 135.88B
EPS 3.30
P/E Ratio 18.74
Div & Yield 4.28 (3.96%)

Latest News

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1]

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Pfizer

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Pfizer

NORTH CHICAGO, Ill., Nov.

AbbVie Receives US FDA Accelerated Approval For VENCLEXTA® (venetoclax) For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

AbbVie Receives US FDA Accelerated Approval For VENCLEXTA® (venetoclax) For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

- Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are ineligible for intensive chemotherapy[1,2]

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding In Women With Uterine Fibroids At 2018 AAGL Global Congress

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding In Women With Uterine Fibroids At 2018 AAGL Global Congress

-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates In Treatment-Naïve Hepatitis C Patients With Compensated Cirrhosis

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates In Treatment-Naïve Hepatitis C Patients With Compensated Cirrhosis

- EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)[1]

AbbVie To Present At The Evercore ISI Conference

AbbVie To Present At The Evercore ISI Conference

NORTH CHICAGO, Ill., Nov.

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors Of Ongoing Investigation Of AbbVie's Humira Sales Practices

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors Of Ongoing Investigation Of AbbVie's Humira Sales Practices

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc.

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape In The United States Using Comprehensive Dataset

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape In The United States Using Comprehensive Dataset

- New MappingHepC.com website provides HCV community an easily accessible source of chronic HCV epidemiology data

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In AbbVie Inc. Of Class Action Lawsuit And Upcoming Deadline - ABBV

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In AbbVie Inc. Of Class Action Lawsuit And Upcoming Deadline - ABBV

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc.

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Momenta

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Momenta

NORTH CHICAGO, Ill., Nov.

I Don't Know Why, but There Is No Enthusiasm for This Market

The gloom is so thick you can cut it with a knife.

Nibble on This Bearish Strategy in Shake Shack: Market Recon

Nibble on This Bearish Strategy in Shake Shack: Market Recon

SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.

AbbVie Reports Third-Quarter 2018 Financial Results

AbbVie Reports Third-Quarter 2018 Financial Results

- Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

AbbVie Receives European Commission Approval Of VENCLYXTO® (venetoclax) Plus Rituximab For The Treatment Of Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

AbbVie Receives European Commission Approval Of VENCLYXTO® (venetoclax) Plus Rituximab For The Treatment Of Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

- The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a standard of care chemoimmunotherapy regimen¹

AbbVie Announces Positive Results From CLL14, A Phase 3 Trial Evaluating A Venetoclax Combination As First-Line Therapy With A Fixed Duration Of Treatment In Patients With Chronic Lymphocytic Leukemia

AbbVie Announces Positive Results From CLL14, A Phase 3 Trial Evaluating A Venetoclax Combination As First-Line Therapy With A Fixed Duration Of Treatment In Patients With Chronic Lymphocytic Leukemia

- Randomized Phase 3 trial met primary endpoint, demonstrating patients treated with venetoclax plus obinutuzumab had superior progression-free survival (PFS) compared to patients treated with standard of care obinutuzumab plus chlorambucil

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

AbbVie Becomes #64 Most Shorted S&P 500 Component, Replacing Kimco Realty

AbbVie Becomes #64 Most Shorted S&P 500 Component, Replacing Kimco Realty

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Clorox, Sirius XM Radio, New Relic, AbbVie, ShotSpotter and more.

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

Jim Cramer asks if the Fed is trying so hard to cool the economy that it could crush wage growth.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

Jim Cramer takes a look at AbbVie, Greendot, Sherwin-Williams, Visteon, TransEnterix, Duke Energy, Buckeye Partners, Arch Coal and more.

TheStreet Quant Rating: B- (Buy)